The genetic evidence that CBFB loss-of-function mutations are associated with breast cancer raises the question of whether these effects are simply due to loss of RUNX transcriptional function via impaired DNA binding (or reduced protein stability) or whether CBFβ exerts RUNX-independent effects that influence cancer development through an alternative mechanism. The gene discussed is CBFB; the disease is breast cancer.